Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab plus chemotherapy vs chemotherapy alone as first-line treatment for metastatic non-small cell lung cancer
2013-001662-42Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of denosumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Overall survival. Started Sep 2013; status: completed.
02
Drugs
denosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-001662-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001662-42.